In the context of CRC, we demonstrated that hydrogel scaffolds implanted directly at the tumor site could sustainably inhibit EGFR internalization, increase cetuximab binding to tumor cells, and enhance cetuximab‐mediated ADCC activity. This evidence concerns the gene EGFR and neoplasm.